MedTrace Logo

Effect of a Daily Text Reminder on Asthma Medication Use, Symptom Control, and Lung Function in Children

NCT07053839 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2025-07-08

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if a daily text reminder ("AdhasText") can help children with asthma use their inhalers regularly, control their symptoms, and improve their lung function. The main questions it aims to answer are:

Does the daily text reminder improve adherence to inhaled corticosteroids in children with asthma? Does the text reminder help children with asthma control their symptoms better? Does the text reminder improve lung function in children with asthma?

Researchers will compare children who receive the daily text reminder with usual care to children who receive usual care (without the reminder) to see if the text reminder improves adherence, symptom control, and lung function.

Participants will:

Receive a daily text reminder or usual care (no reminder) for 90 days Complete questionnaires about their asthma symptoms at 45 and 90 days Have spirometry tests to measure lung function at the start of the study and 90 days

Conditions

  • Asthma in Children

Interventions

BEHAVIORAL

Daily Text Reminder

The intervention, titled "AdhasText," involved sending a daily SMS reminder to caregivers, specifically mothers of children with asthma. The message, "If you want to stay healthy, you must use your inhaler," was sent at 7:00 p.m. over a 90 days period.

Sponsors & Collaborators

  • ROXANA AZNARAN TORRES

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-22
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • Peru

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07053839 on ClinicalTrials.gov